The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARγ ligands

Prostaglandins and Other Lipid Mediators

Volumn 82, Issue 1-4, 2007, Pages 68-76

  O'Brien, Jamie J ^a   Ray, Denise M ^a   Spinelli, Sherry L ^b   Blumberg, Neil ^b   Taubman, Mark B ^c   Francis, Charles W ^c   Wittlin, Steven D ^c   Phipps, Richard P ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cardiovascular disease; CD40 ligand; Diabetes; Platelet; PPAR ; Thromboxane

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CD40 LIGAND; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; ICOSANOID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN E2; ROSIGLITAZONE; THROMBOXANE A2; TICLOPIDINE;

BIOLOGY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; EPIDEMIC; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; THROMBOCYTE; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE;

BLOOD PLATELETS; EICOSANOIDS; INFLAMMATION; LIGANDS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PPAR GAMMA; VASCULAR DISEASES;

EID: 33845334886     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2006.05.018     Document Type: Review

References (86)

1. Sans S., Kesteloot H., and Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 18 (1997) 1231
2. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115
4. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135
5. Nathan D.M. Long-term complications of diabetes mellitus. N Engl J Med 328 (1993) 1676
6. Vivian E.M. Type 2 diabetes in children and adolescents-the next epidemic?. Curr Med Res Opin 22 (2006) 297
7. Rosenbloom A.L., Joe J.R., Young R.S., and Winter W.E. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22 (1999) 345
8. Bhatia V. IAP National Task Force for Childhood Prevention of Adult Diseases: insulin resistance and Type 2 diabetes mellitus in childhood. Indian Pediatr 41 (2004) 443
9. Kannel W.B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40 (2005) 1215
10. Patel S.R., Hartwig J.H., and Italiano Jr. J.E. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest 115 (2005) 3348
11. Fukami M.H., and Salganicoff L. Human platelet storage organelles. A review. Thromb Haemost 38 (1977) 963
12. Rendu F., and Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 12 (2001) 261
13. Harrison P., and Cramer E.M. Platelet alpha-granules. Blood Rev 7 (1993) 52
14. Bath P.M., and Butterworth R.J. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 7 (1996) 157
15. Brown A.S., Hong Y., de Belder A., et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997) 802
16. Wong T., Pedvis L., and Frojmovic M. Platelet size affects both micro- and macro-aggregation: contributions of platelet number, volume fraction and cell surface. Thromb Haemost 62 (1989) 733
17. Giles H., Smith R.E., and Martin J.F. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 24 (1994) 69
18. Vinik A.I., Erbas T., Park T.S., Nolan R., and Pittenger G.L. Platelet dysfunction in type 2 diabetes. Diabetes Care 24 (2001) 1476
19. Tschoepe D., Menart B., Ferber P., et al. Genetic variation of the platelet-surface integrin GPIIb-IIIa (PIA1/A2-SNP) shows a high association with Type 2 diabetes mellitus. Diabetologia 46 (2003) 984
20. Halushka P.V., Rogers R.C., Loadholt C.B., and Colwell J.A. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 97 (1981) 87
21. Katugampola S.D., and Davenport A.P. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 134 (2001) 1385
22. Akai T., Naka K., Okuda K., Takemura T., and Fujii S. Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus. Horm Metab Res 15 (1983) 523
23. Schafer A., Alp N.J., Cai S., et al. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol 24 (20041720)
24. Sarji K.E., Kleinfelder J., Brewington P., Gonzalez J., Hempling H., and Colwell J.A. Decreased platelet vitamin C in diabetes mellitus: possible role in hyperaggregation. Thromb Res 15 (1979) 639
25. Freedman J.E. CD40 ligand-assessing risk instead of damage?. N Engl J Med 348 (2003) 1163
26. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104
27. Jinchuan Y., Zonggui W., Jinming C., Li L., and Xiantao K. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta 339 (2004) 85
28. Rocca B., Secchiero P., Ciabattoni G., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 99 (2002) 7634
29. Oelz O., Oelz R., Knapp H.R., Sweetman B.J., and Oates J.A. Biosynthesis of prostaglandin D2. 1. Formation of prostaglandin D2 by human platelets. Prostaglandins 13 (1977) 225
30. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 63 (2002) 817
31. Furman M.I., Krueger L.A., Linden M.D., Barnard M.R., Frelinger III A.L., and Michelson A.D. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 43 (2004) 2319
32. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591
33. Andre P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 (2002) 896
34. Danese S., and Fiocchi C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol 25 (2005) 103
35. Inwald D.P., McDowall A., Peters M.J., Callard R.E., and Klein N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92 (2003) 1041
36. Cao H.J., Wang H.S., Zhang Y., Lin H.Y., Phipps R.P., and Smith T.J. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem 273 (1998) 29615
37. Sempowski G.D., Chess P.R., Moretti A.J., Padilla J., Phipps R.P., and Blieden T.M. CD40 mediated activation of gingival and periodontal ligament fibroblasts. J Periodontol 68 (1997) 284
38. Zhang Y., Cao H.J., Graf B., Meekins H., Smith T.J., and Phipps R.P. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol 160 (1998) 1053
39. Elzey B.D., Tian J., Jensen R.J., et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 19 (2003) 9
40. Battaglia E., Biancone L., Resegotti A., Emanuelli G., Fronda G.R., and Camussi G. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am J Gastroenterol 94 (1999) 3279
41. Liu Z., Colpaert S., D'Haens G.R., et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 163 (1999) 4049
42. Phipps R.P. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 97 (2000) 6930
43. Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614
44. Garlichs C.D., Eskafi S., Raaz D., et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 86 (2001) 649
45. Gawaz M., Langer H., and May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 115 (2005) 3378
46. Huo Y., Schober A., Forlow S.B., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9 (2003) 61
47. Varo N., Libby P., Nuzzo R., Italiano J., Doria A., and Schonbeck U. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2 (2005) 81
48. Vaidyula V.R., Rao A.K., Mozzoli M., Homko C., Cheung P., and Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 55 (2006) 202
49. Denis M.M., Tolley N.D., Bunting M., et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 122 (2005) 379
50. Akbiyik F., Ray D.M., Gettings K.F., Blumberg N., Francis C.W., and Phipps R.P. Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104 (2004) 1361
51. Smith B.J., Curtis J.F., and Eling T.E. Bioactivation of xenobiotics by prostaglandin H synthase. Chem Biol Interact 79 (1991) 245
52. Hankey G.J., and Eikelboom J.W. Aspirin resistance. BMJ 328 (2004) 477
53. Cambria-Kiely J.A., and Gandhi P.J. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 14 (2002) 51
54. Szczeklik A., Musial J., Undas A., and Sanak M. Aspirin resistance. J Thromb Haemost 3 (2005) 1655
55. Becker D.M., Segal J., Vaidya D., et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295 (2006) 1420
56. Chew D.P., and Bhatt D.L. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep 3 (2001) 63
57. Chew D.P., Bhatt D.L., Sapp S., and Topol E.J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103 (2001) 201
58. Steinhubl S.R., Tan W.A., Foody J.M., and Topol E.J. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb/IIIa Inhibitor for stenting. JAMA 281 (1999) 806
59. Bennett C.L., Connors J.M., Carwile J.M., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342 (2000) 1773
60. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006)
61. Bhatt D.L., and Topol E.J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Am Heart J 148 (2004) 263
62. Issemann I., and Green S. Cloning of novel members of the steroid hormone receptor superfamily. J Steroid Biochem Mol Biol 40 (1991) 263
63. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996) 354
64. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., and Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358 (1992) 771
65. Chung S.W., Kang B.Y., Kim S.H., et al. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 275 (2000) 32681
66. Ali F.Y., Davidson S.J., Moraes L.A., et al. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ. Faseb J 20 (2006) 326
67. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270 (1995) 12953
68. Irons B.K., Greene R.S., Mazzolini T.A., Edwards K.L., and Sleeper R.B. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 26 (2006) 168
69. Pineda Torra I., Gervois P., and Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 10 (1999) 151
70. Torra I.P., Chinetti G., Duval C., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 12 (2001) 245
71. de Faire U., Ericsson C.G., Grip L., Nilsson J., Svane B., and Hamsten A. Secondary preventive potential of lipid-lowering drugs. The bezafibrate coronary atherosclerosis intervention trial (BECAIT). Eur Heart J 37 17 Suppl. F (1996)
72. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410
73. Fagerberg B., Edwards S., Halmos T., et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 (2005) 1716
74. Oakes N.D., Thalen P., Hultstrand T., et al. Tesaglitazar, a dual PPARα/γ agonist, ameliorates glucose and lipid intolerance in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 289 (2005) R938
75. Nolte R.T., Wisely G.B., Westin S., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137
76. Misra P., Chakrabarti R., Vikramadithyan R.K., et al. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J Pharmacol Exp Ther 306 (2003) 763
77. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 (1995) 803
78. Soderstrom M., Wigren J., Surapureddi S., Glass C.K., and Hammarstrom S. Novel prostaglandin D(2)-derived activators of peroxisome proliferator-activated receptor-gamma are formed in macrophage cell cultures. Biochim Biophys Acta 1631 (2003) 35
79. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 (1995) 813
80. McIntyre T.M., Pontsler A.V., Silva A.R., et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA 100 (2003) 131
81. Hatae T., Wada M., Yokoyama C., Shimonishi M., and Tanabe T. Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem 276 (2001) 46260
82. Hertz R., Berman I., Keppler D., and Bar-Tana J. Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR). Eur J Biochem 235 (1996) 242
83. Lim H., and Dey S.K. PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metab 11 (2000) 137
84. 2) synthesis by Raf signaling: failure of PGI2 to activate PPARbeta. Febs J 273 (2006) 170
85. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94 (1997) 4312
86. van Bilsen M., van der Vusse G.J., Gilde A.J., Lindhout M., and van der Lee K.A. Peroxisome proliferator-activated receptors: lipid binding proteins controlling gene expression. Mol Cell Biochem 239 (2002) 131